We are a clinical stage oncology therapeutics company developing a paradigm shift in regards to the treatment of cancer
Lead Product Candidate – OLX01, is entering Phase II clinical development for pancreatic cancer.
Ongoing Product Development – Pipeline of drug candidates targeting NSCL, ovarian and colorectal.
Treatment Efficacy – Targeting metabolic dysfunction avoids the pitfalls of the broad toxicity of platinum-based therapies, enhances the cancer cells sensitivity to chemotherapy & immunotherapy and enhances p53 mediated cellular apoptosis in cancer cells.
Experienced Leadership – 100 years of combined pharma experience and 20 products commercialized.
Performance History – Over 1,200 patients safely and effectively treated.
The Problem – Targeting cancers with high mortality and limited treatment options
Meet Our Team
Meet Our Board of Directors
“We are constantly discovering and innovating to make a meaningful impact for the patients we serve. We are pushing the boundaries on what science and technology can do, making the impossible, possible.”